Effect of cyclosporine on the uptake of monoclonal antibody to cardiac myosin.
Monoclonal antibody to cardiac myosin labeled with indium-111 diethylenetriamine pentaacetic acid holds promise as a noninvasive marker of cardiac graft rejection. Uptake of antibody has correlated with histologic evidence of rejection in nonimmunosuppressed animals. Whether this correlation will apply with immunosuppression has important clinical implications. Fifty-two heterotopic heart transplantations were performed between isogeneic and nonisogeneic strains of rats. Cyclosporine-treated (15 mg/kg day subcutaneously for 9 days) and untreated control animals were killed on day 9, 48 hours after injection of radiolabeled antibody. Donor and recipient hearts were submitted for scintillation scanning and histologic analysis. In untreated animals, antibody uptake was significantly greater in nonisogeneic than in isogeneic donor hearts, correlating with a significantly higher rejection score and increased myocyte necrosis in the former. Between isogeneic groups, cyclosporine-treated donor hearts had significantly higher antibody uptake and donor/native antibody uptake ratios than did untreated isogeneic hearts. There was, however, no significant difference in the histologic degree of rejection or myocyte necrosis between isogeneic groups. Between cyclosporine-treated and untreated nonisogeneic animals, donor heart antibody uptake and donor-native heart antibody uptake ratios were not significantly different. Nonetheless, the histologic grade of rejection and presence of myocyte necrosis was significantly greater in untreated than in treated nonisogeneic hearts. There were no abnormalities in the native hearts. In this model, cyclosporine treatment correlates with an increased uptake of antimyosin antibody in both isogeneic and nonisogeneic donor hearts, out of proportion to histologic evidence of rejection or myocyte necrosis. This effect may lead to false-positive results in clinical tests utilizing antimyosin antibody uptake as a marker of rejection in the presence of cyclosporine therapy.
Allen
M D
MD
Department of Nuclear Medicine, University of Washington, Seattle.
Shoji
Y
Y
Fujimura
Y
Y
Eary
J F
JF
Reichenbach
D D
DD
Thomas
R
R
Gordon
D
D
D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism; D016572:Cyclosporine / Q000494:pharmacology*; D006084:Graft Rejection / Q000187:drug effects / Q000276:immunology; D016027:Heart Transplantation / Q000276:immunology*; D007205:Indium Radioisotopes; D009206:Myocardium / Q000276:immunology*; D009218:Myosins / Q000276:immunology*; D004369:Pentetic Acid; D051381:Rats; D011919:Rats, Inbred Strains
D000911:Antibodies, Monoclonal; D007205:Indium Radioisotopes; D004369:Pentetic Acid; D016572:Cyclosporine; D009218:Myosins